Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study.

Clinical Drug Investigation
Jörg MahlichClaus Wolff-Menzler

Abstract

Long-acting injectable (LAI) antipsychotics can reduce relapse, hospitalization, and costs in patients with schizophrenia. However, real-world evidence assessing the impact of treatment with LAIs in Germany is limited. To provide updated evidence on the impact of LAI initiation on hospitalization rates and therapy costs. Using a mirror-image design, claims data of 850 German patients with schizophrenia who initiated treatment with LAIs during 2013-2015 was retrospectively analyzed. For the included patients, costs and resource utilization were compared for the 12 months before the index date (first initiation of LAI) and the 12 months after the index date. Annual treatment costs, hospitalization rates, ambulatory visits, sick leaves and medical aids were assessed. Two models were used to evaluate hospitalization and its costs. In model 1, hospitalization during the index date (first LAI prescription in 2013-2015) was allocated to the "pre-" time interval, while in model 2 it was neither attributed to the pre- nor to the post-index date. Regression analysis was performed to identify patients who benefited the most in terms of cost reduction from LAI initiation. Medication costs were significantly higher post-switching to LAI com...Continue Reading

References

Apr 2, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Stephen AlmondTraolach Brugha
Jun 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Martin KnappPablo Lapuerta
Dec 30, 2006·The Journal of Clinical Psychiatry·Stephan HeresStefan Leucht
Aug 11, 2007·International Clinical Psychopharmacology·Stephan HeresFrank-Gerald Pajonk
Sep 20, 2007·Expert Opinion on Drug Safety·Camilla Haw, Jean Stubbs
Jun 28, 2008·Journal of Psychopharmacology·M X PatelA David
Mar 24, 2009·Journal of Psychopharmacology·M X PatelA S David
Jan 20, 2010·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Michael WillisUlf Persson
Aug 6, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wolfgang GaebelEnrico Smeraldi
Mar 3, 2011·The American Journal of Psychiatry·Jari TiihonenPasi Korhonen
Feb 22, 2012·Advances in Therapy·Helen KitchenPat Sacco
Jun 22, 2012·BMC Psychiatry·Mario FioravantiMaria Elena Cinti
Aug 4, 2012·International Clinical Psychopharmacology·Alfredo Carlo AltamuraPaolo Girardi
Feb 20, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Simon FreyTom Stargardt
Aug 27, 2013·Applied Health Economics and Health Policy·Jan ZeidlerStephan Heres
Sep 7, 2013·Journal of Medical Economics·Marie-Hélène LafeuilleMei Sheng Duh
Nov 16, 2013·The Journal of Clinical Psychiatry·Taishiro KishimotoChristoph U Correll
May 2, 2014·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Andreas SchreinerMathias Zink
May 24, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·S Frey
Jun 6, 2015·ClinicoEconomics and Outcomes Research : CEOR·Jörg MahlichYoshimichi Saito
Oct 4, 2015·Schizophrenia Research·Andreas SchreinerLudger Hargarter
Apr 1, 2017·Clinical Drug Investigation·Stephane CheungSunny Tsukazawa
Jan 31, 2018·Patient Preference and Adherence·John Fp BridgesAnne de Jong-Laird
Jun 30, 2018·European Psychiatry : the Journal of the Association of European Psychiatrists·Francesco PietriniAndrea Ballerini

❮ Previous
Next ❯

Citations

Apr 13, 2021·European Psychiatry : the Journal of the Association of European Psychiatrists·José Manuel OlivaresUNKNOWN PROSIGO Study Group
Jul 24, 2021·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Chi-Un PaePrakash S Masand

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here